Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Trial Profile

Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin (Primary) ; Sorafenib (Primary)
  • Indications Cholangiocarcinoma; Liver cancer
  • Focus Therapeutic Use
  • Acronyms Alliance

Most Recent Events

  • 03 Aug 2022 Status changed from active, no longer recruiting to completed.
  • 08 Jun 2021 Results of an analysis assessing genetic predictors of sorafenib-induced toxicities from two clinical studies: ALLIANCE and TARGET presented at the 57th Annual Meeting of the American Society of Clinical Oncology
  • 17 Jan 2021 Results assesing radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma by using data from this study presented at the 2021 Gastrointestinal Cancers Symposium.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top